» Articles » PMID: 11796152

Neurobiology of the Nicotine Withdrawal Syndrome

Overview
Publisher Elsevier
Date 2002 Feb 14
PMID 11796152
Citations 125
Authors
Affiliations
Soon will be listed here.
Abstract

The aversive aspects of withdrawal from chronic nicotine exposure are thought to be an important motivational factor contributing to the maintenance of the tobacco habit in human smokers. Much emphasis has been placed on delineating the underlying neurobiological mechanisms mediating different components of the nicotine withdrawal syndrome. Recent studies have shown that both central and peripheral populations of nicotinic acetylcholine receptors (nAChRs) are involved in mediating somatic signs of nicotine withdrawal as measured by the rodent nicotine abstinence scale. However, only central populations of nAChRs are involved in mediating affective aspects of nicotine withdrawal, as measured by elevations in brain-stimulation reward thresholds and conditioned place aversion. Nicotine interacts with several neurotransmitter systems, including acetylcholine, dopamine, opioid peptides, serotonin, and glutamate systems. Evidence so far suggests that these neurotransmitters play a role in nicotine dependence and withdrawal processes. The available evidence also suggests that different underlying neurochemical deficits mediate somatic and affective components of nicotine withdrawal. The aim of the present review is to discuss preclinical findings concerning the neuroanatomical and neurochemical substrates involved in these different aspects of nicotine withdrawal.

Citing Articles

Changes in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats.

Ayman J, Buzas A, Dochnal R, Palotai M, Jaszberenyi M, Bagosi Z Biomedicines. 2025; 13(1).

PMID: 39857727 PMC: 11761252. DOI: 10.3390/biomedicines13010143.


Effects of Tobacco Use on the Macrostructure and Microstructure of Sleep in Patients with OSA.

Ji W, Shi L, Ji Z, Zhao Z, Lin L, Wang X Nat Sci Sleep. 2024; 16:1849-1868.

PMID: 39634156 PMC: 11615015. DOI: 10.2147/NSS.S480116.


SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats.

Braunscheidel K, Voren G, Fowler C, Lu Q, Kuryatov A, Cameron M Front Mol Neurosci. 2024; 17:1459098.

PMID: 39346680 PMC: 11428108. DOI: 10.3389/fnmol.2024.1459098.


Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy.

Nianpanich S, Rodsiri R, Islamie R, Limpikirati P, Thanusuwannasak T, Vajragupta O Psychopharmacology (Berl). 2024; 241(12):2485-2495.

PMID: 39177808 DOI: 10.1007/s00213-024-06675-w.


Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options.

Corley C, Craig A, Sadek S, Marusich J, Chehimi S, White A Pharmacol Biochem Behav. 2024; 243():173836.

PMID: 39067531 PMC: 11344688. DOI: 10.1016/j.pbb.2024.173836.